DSM-Firmenich

Nutrition's good 'health'

18/11/20 -"We have factored in our more positive stance regarding DSM's future strategy in Nutrition, which goes much closer to the individual needs to stay healthy. This will lead to a higher profitability as ..."

PDF page sample
Pages
69
Language
English
Published on
18/11/20
Download
You may also be interested by these reports :
31/07/26
Fuchs reported strong Q2 numbers, supported by positive pricing and market share gains – likely temporary. Growth in sales and earnings was recorded ...
31/07/26
Clariant reported strong Q2 results, with outperformance across segments against street estimates. The performance was led primarily by pricing on a ...
31/07/26
The group reported expected results for Q226, with no significant surprises in operational performance or outlook. Management reiterated confidence ...
30/07/26
Symrise delivered a clear sequential acceleration in Q2, led by Food & Beverage, Consumer Fragrance, and Aroma Molecules. The release is stronger on ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO